The pandemic has jolted many pharma firms into “reimagining” various aspects of their operations with technology, digitization and automation being the key operative levers to enable change across processes. Building supply chain resilience is also seen as pivotal after COVID-19 exposed crippling weaknesses in complex globalized networks.
In an interview with In Vivo, McKinsey & Company senior partner Vikas Bhadoria discussed the shape of things to come...